NuVasive, Inc.

476 articles about NuVasive, Inc.

• Results Validating the Versatility of NuVasive's MaXcess® Retractor in Prone Single-Position XLIF® and Posterior Fixation Published in The European Spine Journal

  2/13/2020

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the results of the study, "Prone single-position extreme lateral interbody fusion (pro-XLIF): preliminary results,

• NuVasive Announces Conference Call and Webcast of Fourth Quarter and Full Year 2019 Results

  2/4/2020

  NuVasive, Inc. announced the Company will release its fourth quarter and full year 2019 earnings results on Thursday, February 20, 2020 after the close of the market.

• NuVasive Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue Results

  1/13/2020

  NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced preliminary unaudited revenue results for the fourth quarter and full year 2019.

• NuVasive to Participate in 38th Annual J.P. Morgan Healthcare Conference

  1/6/2020

  NuVasive, Inc. announced that management will present at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Wednesday, Jan. 15, at 10:00 a.m. PT/1:00 p.m. ET..

• NuVasive Appoints Matthew K. Harbaugh as Chief Financial Officer

  1/2/2020

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Matthew K. Harbaugh as executive vice president and chief financial officer (CFO) effective immediately.

• NuVasive Receives FDA Clearance for Expanded Multi-Level Use of CoRoent Small Interlock™ System for the Cervical Spine

  11/21/2019

   NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company received U.S. Food and Drug Administration (FDA) 510(k) clearance for expanded indications for the CoRoent Small Interlock™ system.

• NuVasive to Participate as Double Diamond Sponsor at the 13th International Congress on Early Onset Scoliosis and Host the MAGEC® Users Meeting

  11/14/2019

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will participate as a double diamond sponsor at the 13th International Congress on Early Onset Scoliosis (ICEOS), November 21-22, 2019 at the Westin Peachtree Plaza in Atlanta.

• NuVasive to Participate as Gold Sponsor at the Cervical Spine Research Society 47th Annual Meeting

  11/13/2019

   NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will participate as a gold sponsor at the Cervical Spine Research Society (CSRS) 47th Annual Meeting, November 21-23, 2019 at the New York Marriott Marquis in New York City.

• NuVasive to Present at the 28th Annual Credit Suisse Healthcare Conference

  11/4/2019

  NuVasive, Inc. announced that management will present at the 28th Annual Credit Suisse Healthcare Conference at The Phoenician in Scottsdale, Arizona on Tuesday, November 12, 2019, at 1:50 p.m. MST/ 3:50 p.m. EST.

• Ophthalmology Times® Announces Winners of 3rd Annual Research Scholar Honoree Program

  10/30/2019

  This program offers a unique opportunity for fellows and residents to share notable retina research with peers and mentors.

• NuVasive Announces Third Quarter 2019 Financial Results

  10/30/2019

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended September 30, 2019.

• NuVasive Announces Conference Call and Webcast of Third Quarter 2019 Results

  10/14/2019

  The Company will release its third quarter 2019 earnings results on Wednesday, October 30, 2019 after the close of the market.

• NuVasive to Participate as Gold Sponsor at the EUROSPINE 2019 Annual Meeting

  10/9/2019

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate as a gold sponsor at the EUROSPINE 2019 Annual Meeting held October 16-18, 2019 in Helsinki, Finland.

• NuVasive to Demonstrate Enabling Technologies to Accelerate the Adoption of Less Invasive Spine Surgery at NASS 2019

  9/25/2019

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will highlight its enabling technologies at the North American Spine Society (NASS) Annual Meeting, September 25-28, 2019 at McCormick Place in Chicago.

• NuVasive LessRay® Platform Wins 2019 Spine Technology Award from Orthopedics This Week

  9/23/2019

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its LessRay® radiation reduction and workflow enhancement platform won the 2019 Spine Technology Award presented by Orthopedics This Week, a widely read publication in the orthopedics industry

• NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting

  9/11/2019

  Scoliosis Research Society (SRS) 54th Annual Meeting held September 18-21, 2019 in Montréal, Canada.

• NuVasive Expands Cervical Advanced Materials Science™ Portfolio with Launch of Porous Titanium Implant

  9/5/2019

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the commercial launch of Modulus® Cervical, a porous titanium interbody implant for cervical applications.

• NuVasive Announces Jerome Bettis, NFL Pro Football Hall of Famer, as Brand Ambassador

  8/28/2019

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced Jerome Bettis, NFL Pro Football Hall of Famer and 2006 Super Bowl champion, will serve as a Company brand ambassador.

• NuVasive to Participate in Investor Events in September 2019

  8/26/2019

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that management will participate in the following investor events in Septembe

• NuVasive Expands its Advanced Materials Science™ Portfolio to Offer Porous Titanium Spine Implants for all TLIF Procedures

  8/20/2019

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the commercial launch of Modulus® TLIF-A, a porous titanium spine implant engineered for the transforaminal lumbar interbody fusion (TLIF) procedure.